Monday, July 24, 2023
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines for infectious diseases and cancer in the United States and internationally. The company through its patented Modified Vaccinia Ankara-Virus Like Particle vaccine platform develops various vaccines. It is developing various vaccines that are in human clinical trials, and preclinical research and development phases, including vaccines against human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; United States Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; Peking University; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies, Inc.; Viamune, Inc.; Vaxeal Holding SA; CaroGen Corporation; Virometix AG; and Leidos, Inc. GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia.
Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Patent Issuance Covers The GeoVax Ebolavirus. GeoVax announced the issuance of a US patent covering its ebolavirus vaccine made using its VLP (virus-like particle) technology. The vaccine uses an MVA viral vector to deliver genes to elicit an immune response against the virus. The patent claims cover multiple ebolavirus strains including Sudan ebolavirus, Zaire ebolavirus, Taï Forest ebolavirus, and Reston ebolavirus. We see this issuance as both a commercial and scientific milestone for GeoVax.
MVA-VLP Is A Novel Vaccine Technology Platform. The GeoVax MVA-VLP is a novel vaccine platform that delivers genes to produce VLPs within a person’s cells. After vaccination, the genes express the viral proteins which then assemble into VLPs. These VLPs are similar enough to the virus to be recognized and elicit immune protection but are not infectious or capable of replicating in the body. Preclinical studies have shown immune responses that are similar to live-attenuated virus vaccines, with both strong humoral and cellular immunity as well as greater safety from the MVA vector.
Get the Full Report
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.